The Evaluation of Vitiligous Lesions Repigmentation After the Administration of Atorvastatin Calcium Salt and Simvastatin-acid Sodium Salt in Patients With Active Vitiligo

Exclusion Criteria

• •1. pregnancy or breast-feeding
• •2. diagnosis of segmental, mixed, unclassified or undefined vitiligo
• •3. hypersensitivity to simvastatin or atorvastatin
• •4. any statins use within 8 weeks preceding eligibility screening
• •5. systemic immunosuppressive/immunomodulating i.e. cyclosporine A, corticosteroids within 4 weeks preceding eligibility screening or azathioprine, methotrexate, mycophenolate mofetil, Janus kinase - JAK within 8 weeks preceding eligibility screening
• •6. phototherapy due to vitiligo or any other medical conditions within the 4-week period preceding eligibility screening
• •7. any topical or systemic additional vitiligo treatment (e.g. antioxidants, ginkgo biloba, dermo-cosmetics) within 4 weeks preceding screening
• •8. surgical treatment of vitiligous lesions within past 4 weeks
• •9. hypersensitivity to statins
• •10. decompensated autoimmune or internal diseases
• •11. alcohol or drug abuse
• •12. skin malignancies (currently or history of skin malignancy within 5 years preceding screening)
• •13. presence of skin characteristics that may interfere with study assessments
• •14. patients currently participating in any other clinical study
• •15. uncooperative patients
• •none of the above can be met